Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this survey was to understand the safety and efficacy of PAXIL tablets ("PAXIL", hereinafter) when it was started at 20 mg/day in subjects with depression or in a depressed state.

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Paroxetine

Criteria

Inclusion Criteria:

• Patients with depression or in a depressed state

• Patients who start taking paroxetine at 20mg a day

Exclusion Criteria:

• Patients who have been treated with paroxetine prior to this investigation

• Patients with hypersensitivity to paroxetine

• Patients taking monoamine oxidase inhibitors (MAOIs) or within 2 weeks of stopping treatment with MAOIs

• Concomitant use in patients taking pimozide